Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure

British Journal of Cancer

Volumn 83, Issue 4, 2000, Pages 431-437

  Freyer, G ^a   Rougier, P ^b   Bugat, R ^c   Droz, J P ^d   Marty, M ^e   Bleiberg, H ^f   Mignard, D ^g   Awad, L ^g   Herait, P ^g   Culine, S ^h   Trillet Lenoir, V ^a  

^a CENTRE HOSPITALIER LYON SUD   (France)

^b HÔPITAL AMBROISE PARÉ   (France)

^c INSTITUT CLAUDIUS REGAUD   (France)

^d CENTRE LÉON BÉRARD   (France)

^e SAINT LOUIS HOSPITAL   (France)

^f JULES BORDET INSTITUTE   (Belgium)

^g SANOFI   (France)

^h CENTRE VAL D AURELLE   (France)

Author keywords

Colorectal cancer; Irinotecan; Prognostic factors; Survival; Toxicity

Indexed keywords

BILIRUBIN; CARCINOEMBRYONIC ANTIGEN; CREATININE; FLUOROURACIL; HEMOGLOBIN; IRINOTECAN;

ADULT; AGED; ARTICLE; CANCER CONTROL; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CREATININE BLOOD LEVEL; DIARRHEA; DRUG EFFICACY; FEMALE; HEMOGLOBIN DETERMINATION; HUMAN; LEUKOCYTE COUNT; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; NEUTROPENIA; PERITONEUM METASTASIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS;

EID: 0033913981     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.2000.1303     Document Type: Article

References (20)

1. Advanced Colorectal Cancer Meta-analysis Project (1992) 2. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rates. J Clin Oncol 10: 896-903
2. Advanced Colorectal Cancer Meta-analysis Project (1994) Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. J Clin Oncol 5: 960-969
3. Ahlgren JD, Trocki O and Gullo JJ (1991) Protracted infusion of 5FU with weekly low dose cisplatin as a second line therapy in patients with metastatic colorectal cancer who have failed 5-FU monotherapy. Cancer Invest 9: 27-33
4. Allen M, Cunningham D and Schmitt C (1998) The importance of stabilization as an endpoint in the treatment of metastatic colorectal carcinoma: recent quality of life studies. Anticancer Drugs 9: 783-790
5. Bertrand M, Doroshow JH, Multhauf P, Blayney DW, Carr BI and Cecchi G (1992) High dose continuous infusion folinic acid and bolus 5-fluorouracil in patients with advanced colorectal cancer: a randomized trial. J Clin Oncol 10: 904-911
6. Brienza S, Levi F and Valori VM (1993) Intensified (every 2 weeks) chronotherapy with 5-fluorouracil folinic acid and oxaliplatin in previously treated patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 12: 125, 620
7. Canal P, Gay C, Dezeuze A, Douillard JY, Bugat R, Brunet R, Adenis A, Herait P, Lokiec F and Mathieu-Boue A (1996) Pharmacokinetics and pharmacodynamics of Irinotecan during a phase II clinical trial in colorectal cancer. J Clin Oncol 14: 2688-2695
8. Chabot GG, Abigerges A, Catimel G, Culine S, de Forni M, Extra JM, Majoubi M, Herait P, Armand JP and Bugat R (1995) Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11 ) and active metabolite SN-38 during phase I trials. Ann Oncol 6: 141-151
9. Cunningham D, Pyrrhönen S, James RD, Punt CJ, Hickish TF, Heikkila R, Yohannesen TD, Starkkhammar H, Topham CA, Awwad L, Jacques C and Herait P (1998) Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. The Lancet 352: 1401-1418
10. de Gramont A, Bosset JF, Milan C, Rougier P, Bouché O, Etienne PL, Morvan F, Louvet C, Guillot T, François E and Bedenne L (1997) Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a french intergroup study. J Clin Oncol 15: 808-815
11. de Gramont A, Vignoud J, Tournigand C, Louvet C, Varette C, Raymond E, Moreau S, Le Bail N and Krulik M (1997) Oxaliplatin with high dose folinic acid and 5 fluorouracil 48 hours infusion in pretreated metastatic colorectal cancer. Eur J Cancer 33: 214-219
12. Glimelius B, Hoffman K, Graf W, Páhlman L and Sjödén PO (1994) Quality of life during chemotherapy in patient with symptomatic advanced colorectal cancer. Cancer 73: 556-562
13. Izzo J, Cvitkovic E, Zarba J, Chadjaa M, May-Levin F and Riggi M (1992) Low dose 5FU continuous infusion in advanced colorectal cancer: Clinical evidence for reversal of acquired/intrinsic resistance to 5-FU or 5-FU folinic Acid. Ann Oncol 5: 38-43
14. Nordic Gastrointestinal Tumor Adjuvant Project (1992) Expectancy of primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial. J Clin Oncol 10: 904-911
15. Pitot HC, Wender DB, O'Connell MJ, Schroeder G, Goldberg RM, Rubin J, Mailliard JA, Knost JA, Ghosh C, Kirschling PJ, Levitt R and Windschitl HE (1997) Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. J Clin Oncol 15: 2910-2919
16. Rougier P, Bugat R, Douillard JY, Culine S, Suc E, Brunet P, Becouarn Y, Ychou M, Marty M, Extra JM, Bonneterre J, Adenis A, Seitz JF, Ganem G, Namer M, Conroy T, Negrier S, Merrouche Y, Burki F, Mousseau M, Herait P and Mahjoubi M (1997) Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 15: 251-260
17. Rougier P, Milan C, Lazorthes F, Fourtanier G, Partensky C, Baumel H and Faivre J (1995) Prospective study of prognostic factors in patients with unresected hepatic metastases from colorectal cancer. Br J Surg 82: 1397-1400
18. Rougier Ph, Van Cutsem E, Bajetta E, Niederle N, Possinger C, Labianca, Navarro M, Moraut R, Bleigerg H, Nils J, Awad L, Herait P and Jacques C (1998) Randomized trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. The Lancet 352: 1407-1412
19. Saltz L, Danenberg K and Paty P (1998) High thymidylate synthase expression does not preclude activity of CPT-11 in colorectal cancer. Proc Am Soc Clin Oncol 281a: 1210
20. Scheithauer W, Rosen H, Kornek GV, Sebesta C and Depisch D (1993) Randomized comparison of combination chemotherapy plus supportive care or supportive care alone in patients with metastatic colorectal cancer. BMJ 306: 752-755